Using MR-Linac for precise radiotherapy in cancer treatment
The Second Affiliated Hospital of Hainan Medical University
This study is testing if a new type of radiation therapy using MR-Linac can help cancer patients have better treatment outcomes and improve their quality of life.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | The Second Affiliated Hospital of Hainan Medical University Academic / other |
| Locations | 1 site (Haikou) |
| Trial ID | NCT06531681 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of magnetic resonance-guided linear accelerator (MR-Linac) technology in delivering precision radiotherapy for tumors. It will analyze various outcomes including overall response rate, progression-free survival, disease control rate, overall survival, and the incidence of adverse reactions. Additionally, the study will assess the quality of life of patients using standardized measures and evaluate dosimetric parameters related to treatment. The study will involve patients aged 18-75 who have undergone imaging or treatment with MR-Linac.
Who should consider this trial
Good fit: Ideal candidates are patients aged 18-75 with an ECOG score of 0-2 who are undergoing or have undergone treatment with MR-Linac.
Not a fit: Patients with contraindications to MRI or severe comorbidities that prevent them from tolerating radiotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved tumor response rates and reduced side effects for cancer patients undergoing radiotherapy.
How similar studies have performed: While the use of MR-Linac is a relatively novel approach, preliminary studies have shown promising results in improving precision in radiotherapy.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients are undergoing or have undergone imaging or treatment at the MR linac; * Age 18-75 years, male or female; * ECOG score 0-2, life expectancy \> 6 months; * Patients provide written informed consent. Exclusion Criteria: * Contraindications to MRI, such as claustrophobia and metallic or electronic implants incompatible with MRI; * The presence of severe comorbidities that, in the opinion of the investigator, · preclude the toleration or completion of radiotherapy; * Acute inflammatory disease requiring systemic therapy; * The presence of active infectious disease; * Pregnant women, nursing mothers, and patients planning to have children during the study period.
Where this trial is running
Haikou
- The Second Affiliated Hospital of Hainan Medical University — Haikou, China (Recruiting)
Study contacts
- Principal investigator: yuecan zeng, doctor — The Second Affiliated Hospital of Hainan Medical University
- Study coordinator: junnv xu, doctor
- Email: xujunnv@sina.com
- Phone: 18208946196
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.